Experimental drug AL101 shows promise in shrinking rare cancer before surgery
NCT ID NCT04973683
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 36 times
Summary
This early-phase trial tests the safety and potential benefits of the drug AL101 given before standard surgery for people with a rare salivary gland cancer called adenoid cystic carcinoma that has a specific genetic change (NOTCH activation). The study involves 14 adults whose cancer can be surgically removed. AL101 works by blocking enzymes that help cancer cells grow, and researchers hope it may help control the disease before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.